BTIG Downgrades DermTech Inc. (DMTK) to Neutral

Go back to BTIG Downgrades DermTech Inc. (DMTK) to Neutral

Lake Street Capital Markets Downgrades DermTech Inc. (DMTK) to Hold

April 19, 2024 7:29 AM UTC

Lake Street Capital Markets analyst Thomas Flaten downgraded DermTech Inc. (NASDAQ: DMTK) from Buy to Hold with a price target of $0.63.

For an analyst ratings summary and ratings history on DermTech Inc. click here. For more ratings news on DermTech Inc. click here.

Shares of DermTech Inc. closed at $0.59 yesterday.

... More

DermTech (DMTK) to Explore Strategic Alternatives and Implement Restructuring Plan

April 18, 2024 4:16 PM UTC

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring strategic alternatives to maximize stockholder value. Potential strategic alternatives that may be explored or evaluated include an acquisition, merger,... More